Amarin’s (AMRN) Vascepa is currently approved to treat around 3.8 million Americans with high triglycerides, as an adjunct to diet.
Year-to-date, Amarin (AMRN) stock is up nearly 20% due to Pfizer buyout chatter. According to rumors, the pharma giant is interested in making …
A lot of Amarin (AMRN) stock bulls expected shares to fly up toward $30 following shockingly good results of the company’s Reduce-It cardiovascular …
Amarin (AMRN) has been Wall Street’s biggest standout of 2018, with shares skyrocketing nearly 240%. The biggest question for investors, then, is whether …
Shares of Amarin (AMRN), an Irish biopharma that markets a prescription fish oil medication called Vascepa, are on the move following the company’s …
Amarin (AMRN) has had a lot of attention over its fish oil pill Vascepa, which aims to help those with cardiovascular problems and …
70-year-old Israel “Izzy” Englander, worth $6 billion to date, was born the same year as the state of Israel, and just one year …
In early November, fish oil drug maker Amarin (AMRN) presented data called REDUCE-IT at the American Heart Association scientific sessions for a medication …
Andrew Spokes, managing partner at Farallon Capital Management stepped in for founder Thomas Steyer in 2013 and has been hedging big bets for …
Amarin (AMRN) stock tumbled nearly 5% yesterday after European regulators deemed all Omega-3 fatty acid pills/medicines in Europe ineffective in preventing cardiovascular events. …
